Home Newsfeeds Telsey Advisory Group Maintains Outperform on Five Below, Raises Price Target to $175

Telsey Advisory Group Maintains Outperform on Five Below, Raises Price Target to $175

Telsey Advisory Group analyst Joseph Feldman maintains Five Below (NASDAQ:FIVE) with a Outperform and raises the price target from $150 to $175.

byBenzinga Newsdesk

November 28, 2022

1 minute read

Telsey Advisory Group analyst Joseph Feldman maintains Five Below (NASDAQ:FIVE) with a Outperform and raises the price target from $150 to $175.

Bristol-Myers Squibb, Toast And A Major REIT Stock: CNBC’s ‘Final Trades’

By Priya Nigam

August 11, 9:07 AM

On CNBC’s "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Bristol-Myers Squibb Company (NYSE: BMY), which announced $4 billion aggregate accelerated

BMY

News
Tech

Tesla Executive Echoes Elon Musk On Funding Of Hydrogen Infrastructure: There Is An ‘Illogical Government Addiction’

By Anan Ashraf

January 17, 12:45 AM

Tesla Inc (NASDAQ:TSLA) executive Rohan Patel on Tuesday termed government incentives for the utilization of Hydrogen an ‘illogical…

NKLA

Matterport Sees Q4 EPS $(0.05)-$(0.03) Vs $(0.05) Est.; Revenue $39M-$41M Vs $40.24M Est.; FY23 EPS $(0.23)-$(0.21) Vs $(0.25) Est.; Revenue $157M-$159M Vs $156.86M Est.

By Benzinga Newsdesk

November 6, 6:00 PM

Fourth Quarter and Full Year 2023 OutlookThe Company is providing the following financial guidance for the fourth quarter and full year 2023. The Company is raising its full year guidance for revenue and Non-GAAP loss

MTTR

News

Reported Saturday, 4DMT Presented Injection-Free Subgroup Analyses From 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort In Wet AMD Patients With Severe Disease Activity & High Treatment Burden At The Clinical Trials Summit 2024

By Benzinga Newsdesk

June 10, 3:23 AM

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in the

FDMT

Telsey Advisory Group Maintains Outperform on Five Below, Raises Price Target to $175

Related Posts

Bristol-Myers Squibb, Toast And A Major REIT Stock: CNBC’s ‘Final Trades’

Tesla Executive Echoes Elon Musk On Funding Of Hydrogen Infrastructure: There Is An ‘Illogical Government Addiction’

Matterport Sees Q4 EPS $(0.05)-$(0.03) Vs $(0.05) Est.; Revenue $39M-$41M Vs $40.24M Est.; FY23 EPS $(0.23)-$(0.21) Vs $(0.25) Est.; Revenue $157M-$159M Vs $156.86M Est.

Reported Saturday, 4DMT Presented Injection-Free Subgroup Analyses From 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort In Wet AMD Patients With Severe Disease Activity & High Treatment Burden At The Clinical Trials Summit 2024